Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity

Journal of Pediatric Ophthalmology and Strabismus

Volumn 49, Issue 4, 2012, Pages 230-235

  Li, Wenlin ^a   Jiang, Deyong ^b  

^a SHENZHEN CHILDREN'S HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN; PROTEIN BCL 2; RESVERATROL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; HYPEROXIA; NONHUMAN; OXYGEN TENSION; PROTEIN EXPRESSION; RAT; RETROLENTAL FIBROPLASIA; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT, NEWBORN; OXYGEN; PLATELET AGGREGATION INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RETINOPATHY OF PREMATURITY; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866326993     PISSN: 01913913     EISSN: 19382405     Source Type: Journal    
DOI: 10.3928/01913913-20111129-01     Document Type: Article

References (53)

1. An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991-999.
2. Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115:e518-e525.
3. Sharma R, Gupta VP, Dhaliwal U, Gupta P. Screening for retinopathy of prematurity in developing countries. J Trop Pediatr. 2007;53:52-54.
4. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
5. Smith LE, Wesolowski E, Mclellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
6. Wennersten A, Holmin S, Mathiesen T. Characterization of Bax and Bcl-2 in apoptosis after experimental traumatic brain injury in the rat. Acta Neuropathol. 2003;105:281-288.
7. Strauss KI, Narayan RK, Raghupathi R. Common patterns of bcl-2 family gene expression in two traumatic brain injury models. Neurotox Res. 2004;6:333-342.
8. Iervolino A, Trisciuoglio D, Ribatti D, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 2002;16:1453-1455.
9. Nor JE, Christensen J, Liu J, et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001;61:2183-2188.
10. Wirostko BM. Vascular endothelial growth factor. Ophthalmology. 2007;114:1954-1955.
11. Dieudonne SC, Heij ECL, Diederen RM, et al. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic Res. 2007;39:148-154.
12. Roemer K, Mahyar-Roemer M. The basis for the chemopreventive action of resveratrol. Drugs Today (Barc). 2002;38:571-580.
13. Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res. 2003;523-524:145-150.
14. Reynolds JD. The management of retinopathy of prematurity. Paediatr Drugs. 2001;3:263-272.
15. Raymond MA, Vigneault N, Luyckx V, Hebert MJ. Paracrine repercussions of preconditioning on angiogenesis and apoptosis of endothelial cells. Biochem Biophys Res Commun. 2002;291:261-269.
16. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division: evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995;36:1201-1214.
17. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
18. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47:3135-3142.
19. Maharaj ASR, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168:639-648.
20. Robinson GS, Aiello LP. Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin. 1998;38:89-102.
21. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
22. Fujiuchi Y, Nagakawa O, Murakami K, Fuse H, Saiki I. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol Rep. 2003;10:1001-1006.
23. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009;24:77-81.
24. Jay SM, Shepherd BR, Bertram JP, Pober JS, Saltzman WM. Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation. FASEB J. 2008;22:2949-2956.
25. Arakawa M, Yasutake M, Miyamoto M, Takano T, Asoh S, Ohta S. Transduction of anti-cell death protein FNK protects isolated rat hearts from myocardial infarction induced by ischemia/reperfusion. Life Sci. 2007;80:2076-2084.
26. Burke C, Sinclair K, Cowin G, et al. Intrauterine growth restriction due to uteroplacental vascular insufficiency leads to increased hypoxia-induced cerebral apoptosis in newborn piglets. Brain Res. 2006;1098:19-25.
27. Kienle K, Rentsch M, Müller T, et al. Expression of BCL-2 in liver grafts after adenoviral transfer improves survival following prolonged ischemia and reperfusion in rat liver transplantation. Transplant Proc. 2005;37:439-441.
28. Gobé G, Zhang XJ, Cuttle L, et al. Bcl-2 genes and growth factors in the pathology of ischaemic acute renal failure. Immunol Cell Biol. 1999;77:279-286.
29. Chen MK, Lai JC, Chang CC, Chang JH, Chang YJ, Chen HC. Prognostic impact of Bcl-2 expression on advanced nasopharyngeal carcinoma. Head Neck. 2008;30:1052-1057.
30. Lee KH, Im SA, Oh DY, et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer. 2007;7:63.
31. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res. 2007;13:3585-3590.
32. Contu PC, Contu SS, Moreira LF. Bcl-2 expression in rectal cancer. Arq Gastroenterol. 2006;43:284-287.
33. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, Kim KW. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000;19:4621-4631.
34. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001;15:1798-1800.
35. Olas B, Wachowicz B. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb Res. 2002;106:143-148.
36. O'Connor DJ, Wong RW, Rabie AB. Resveratrol inhibits periodontal pathogens in vitro [published online ahead of print April 25, 2011]. Phytother Res. doi:10.1002/ptr.3501
37. Gao D, Zhang X, Jiang X, et al. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci. 2006;25:78:2564-2570.
38. Li C, Yan Z, Yang J, et al. Neuroprotective effects of resveratrol on ischemic injury mediated by modulating the release of neurotransmitter and neuromodulator in rats. Neurochem Int. 2010;56:495-500.
39. Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem. 2010;17:2442-2455.
40. Das S, Fraga CG, Das DK. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic Res. 2006;40:1066-1075.
41. Lee EO, Lee HJ, Hwang HS, et al. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis. 2006;27:2059-2069.
42. Chen JC, Chen Y, Lin JH, Wu JM, Tseng SH. Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res. 2006;26:1237-1245.
43. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006;231:113-122.
44. Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl). 2007;120:1672-1677.
45. Wu H, Liang X, Fang Y, Qin X, Zhang Y, Liu J. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed Pharmacother. 2008;62:613-621.
46. Cao Z, Fang J, Xia C, Shi X, Jang BH. Trans-3,4,50-tri-hydroxystibene inhibits hypoxia-inducible factor 1 alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res. 2004;10:5253-5263.
47. Park SY, Jeong KJ, Lee J, et al. Hypoxia enhances LPA-induced HIF-1a and VEGF expression: their inhibition by resveratrol. Cancer Lett. 2007;258:63-69.
48. Burkitt MJ, Duncan J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch Biochem Biophys. 2000;381:253-263.
49. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res. 2000;47:549-555.
50. Hua J, Guerin KI, Chen J, et al. Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice. Invest Ophthalmol Vis Sci. 2011;52:2809-2816.
51. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24:2783-2840.
52. Sun C, Hu Y, Liu X, et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappa B in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 2006;165:9-19.
53. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008;7:1020-1035